Loading clinical trials...
Loading clinical trials...
Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues - a Randomized, Double-blind, Placebo-controlled Trial
Conditions
Interventions
Dulaglutide
0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])
Locations
1
Switzerland
Universitätsspital Basel
Basel, Switzerland
Start Date
June 26, 2017
Primary Completion Date
July 30, 2022
Completion Date
August 30, 2022
Last Updated
September 13, 2022
NCT07441928
NCT05733767
NCT07061522
NCT06798324
NCT07013968
NCT06926608
Lead Sponsor
University Hospital, Basel, Switzerland
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions